Literature DB >> 15698590

Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein.

Hai-Rong Wang1, Jian-Jun Li, Cong-Xin Huang, Hong Jiang.   

Abstract

BACKGROUND: Inflammation plays a critic role in atherosclerosis and C-reactive protein (CRP) may directly facilitate the development of a proinflammatory and proatheroscleroitc phenotype. The nuclear factor-kappaB (NF-kappaB) signal transduction is known to play a key role in the expression of these proatherogenic entities including tumor necrosis factor-alpha (TNF-alpha). Much data suggest that statin possess a potential anti-inflammatory effect. However, the effects of statin on the expression of TNF-alpha and activation of NF-kappaB in endothelial cells stimulated by CRP are less studied. We determined the effects of CRP in inducing inflammatory response and the effect of fluvastatin on CRP-dependent inflammatory activation in human cultured endothelial cells.
METHODS: Human vascular endothelial cells were cultured and stimulated by concentrations of CRP (5-100 microg/ml) for 0, 2, 4, 8, 16, 24, and 48 h. Also 10 micromol/l of fluvastatin was pre-incubated for 2 h with cells in the presence of CRP. The activity of transcription factor NF-kappaB was evaluated by electrophoretic mobility shift assay (EMSA). Measurements of TNF-alpha were performed from supernatants of cultured medium in duplicate, using commercial assay kits.
RESULTS: CRP increased the release of TNF-alpha rapidly as a dose-and time-dependent manner. Induction of TNF-alpha was detected at 5 microg/ml and reached a maximum at 100 microg/ml of CRP. The CRP also significantly induces the activation of NF-kappaB in endothelial cells, and those effects were apparently inhibited by 10 micromol/l of fluvastatin, but not complete.
CONCLUSIONS: CRP stimulation result in induction of TNF-alpha and activation of NF-kappaB, and this effect could be significantly inhibited by fluvastatin, suggesting that CRP may play a direct role in atherogenesis by activating endothelial cells, and statins inhibit this response, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of statins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698590     DOI: 10.1016/j.cccn.2004.10.007

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

Review 1.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

2.  Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.

Authors:  Carolyn Hoppe; Eufemia Jacob; Lori Styles; Frans Kuypers; Sandra Larkin; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2017-03-28       Impact factor: 6.998

3.  Treatment with Atorvastatin Provides Additional Benefits to Imipenem in a Model of Gram-Negative Pneumonia Induced by Klebsiella pneumoniae in Mice.

Authors:  Talles Prosperi de Paula; Patrícia Campi Santos; Raquel Duque do Nascimento Arifa; Angélica T Vieira; Ludmila de Matos Baltazar; Thiago Vinícius Ávila; Caio Tavares Fagundes; Zélia Menezes Garcia; Renata Lacerda Lima; Mauro Martins Teixeira; Danielle G Souza
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis.

Authors:  Savaş Demirbilek; Erkan Tas; Kubilay Gurunluoglu; Melih Akin; Rauf T Aksoy; Memet H Emre; Nasuhi E Aydin; Selma Ay; Nilufer Ozatay
Journal:  Pediatr Surg Int       Date:  2006-11-04       Impact factor: 1.827

5.  Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.

Authors:  Xu-Feng Qi; Dong-Heui Kim; Yang-Suk Yoon; Jian-Hong Li; Dan Jin; Yung-Chien Teng; Soo-Ki Kim; Kyu-Jae Lee
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

Review 6.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

7.  Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2008-04-27       Impact factor: 3.786

Review 8.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

Review 9.  Drug repurposing for the treatment of staphylococcal infections.

Authors:  Shankar Thangamani; Haroon Mohammad; Waleed Younis; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 10.  Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.

Authors:  Marios Margaritis; Keith M Channon; Charalambos Antoniades
Journal:  Antioxid Redox Signal       Date:  2014-01-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.